Bionano Genomics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.43
- Today's High:
- $3.85
- Open Price:
- $3.45
- 52W Low:
- $0.6
- 52W High:
- $4.35
- Prev. Close:
- $3.49
- Volume:
- 1081504
Company Statistics
- Market Cap.:
- $236.23 million
- Book Value:
- 0.755
- Revenue TTM:
- $29.52 million
- Operating Margin TTM:
- -465.71%
- Gross Profit TTM:
- $5.95 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -26.84%
- Return on Equity TTM:
- -51.51%
Company Profile
Bionano Genomics Inc had its IPO on 2018-08-21 under the ticker symbol BNGO.
The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Bionano Genomics Inc has a staff strength of 405 employees.
Stock update
Shares of Bionano Genomics Inc opened at $3.45 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.43 - $3.85, and closed at $3.55.
This is a +1.72% increase from the previous day's closing price.
A total volume of 1,081,504 shares were traded at the close of the day’s session.
In the last one week, shares of Bionano Genomics Inc have slipped by -7.79%.
Bionano Genomics Inc's Key Ratios
Bionano Genomics Inc has a market cap of $236.23 million, indicating a price to book ratio of 2.2342 and a price to sales ratio of 22.1355.
In the last 12-months Bionano Genomics Inc’s revenue was $29.52 million with a gross profit of $5.95 million and an EBITDA of $-126881000. The EBITDA ratio measures Bionano Genomics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Bionano Genomics Inc’s operating margin was -465.71% while its return on assets stood at -26.84% with a return of equity of -51.51%.
In Q1, Bionano Genomics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 30.2%.
Bionano Genomics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bionano Genomics Inc’s profitability.
Bionano Genomics Inc stock is trading at a EV to sales ratio of 17.7559 and a EV to EBITDA ratio of -4.0545. Its price to sales ratio in the trailing 12-months stood at 22.1355.
Bionano Genomics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $292.15 million
- Total Liabilities
- $38.14 million
- Operating Cash Flow
- $16.53 million
- Capital Expenditure
- $360000
- Dividend Payout Ratio
- 0%
Bionano Genomics Inc ended 2024 with $292.15 million in total assets and $0 in total liabilities. Its intangible assets were valued at $292.15 million while shareholder equity stood at $231.49 million.
Bionano Genomics Inc ended 2024 with $0 in deferred long-term liabilities, $38.14 million in other current liabilities, 31000.00 in common stock, $-385839000.00 in retained earnings and $77.29 million in goodwill. Its cash balance stood at $4.10 million and cash and short-term investments were $95.81 million. The company’s total short-term debt was $2,517,000 while long-term debt stood at $0.
Bionano Genomics Inc’s total current assets stands at $142.56 million while long-term investments were $0 and short-term investments were $91.70 million. Its net receivables were $6.78 million compared to accounts payable of $15.78 million and inventory worth $33.11 million.
In 2024, Bionano Genomics Inc's operating cash flow was $16.53 million while its capital expenditure stood at $360000.
Comparatively, Bionano Genomics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.55
- 52-Week High
- $4.35
- 52-Week Low
- $0.6
- Analyst Target Price
- $4.06
Bionano Genomics Inc stock is currently trading at $3.55 per share. It touched a 52-week high of $4.35 and a 52-week low of $4.35. Analysts tracking the stock have a 12-month average target price of $4.06.
Its 50-day moving average was $4.71 and 200-day moving average was $10.54 The short ratio stood at 6.07 indicating a short percent outstanding of 0%.
Around 182.5% of the company’s stock are held by insiders while 2793.1% are held by institutions.
Frequently Asked Questions About Bionano Genomics Inc
Similar Industry Stocks (Medical Instruments & Supplies)
Most Active
Top Gainers
Top Losers
About
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.